NIH Funding Announcements

Syndicate content
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 21 hours 56 min ago

Community Partnerships to Advance Research (CPAR) (R21 Clinical Trial Optional)

Mon, 12/18/2017 - 13:20
Funding Opportunity PA-18-381 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages researchers to partner with community groups, using Community Engaged Research (CEnR) methodologies that will enhance relationships and lead to better intervention development and positive health outcomes.
Categories: NIH-Funding

Community Partnerships to Advance Research (CPAR) (R01 Clinical Trial Optional)

Mon, 12/18/2017 - 13:20
Funding Opportunity PA-18-377 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages researchers to partner with community groups, using Community Engaged Research (CEnR) methodologies that will enhance relationships and lead to better intervention development and positive health outcomes.
Categories: NIH-Funding

Community Partnerships to Advance Research (CPAR) (R15 Clinical Trial Not Allowed)

Mon, 12/18/2017 - 13:19
Funding Opportunity PA-18-475 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages researchers to partner with community groups, using Community Engaged Research (CEnR) methodologies that will enhance relationships and lead to better intervention development and positive health outcomes.
Categories: NIH-Funding

Advancing Basic Neurobiology Toward Translation Through Assay Development (R01 Clinical Trials Not Allowed)

Mon, 12/18/2017 - 13:18
Funding Opportunity PAR-18-505 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages research grant applications to develop novel, robust assays to reveal changes in neuronal and/or glial function. The goal is to adapt state-of-the-art measures of basic cellular processes or molecular events that are key mediators of nervous system function into phenotypic assays, with the intent to probe mechanisms or perturbations in an unbiased and efficient manner. These novel assays would provide opportunities to measure neurobiological endpoints to accelerate basic discovery and support target identification and therapeutic development efforts.
Categories: NIH-Funding

Notice of Clarification of NINDS Statement of interest for "Bioengineering Research Partnerships (BRP) (U01 Clinical Trial Optional)"

Mon, 12/18/2017 - 12:45
Notice NOT-NS-18-029 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of Change to Award Information in RFA-AI-17-040 "Cooperative Centers on Human Immunology (U19 Clinical Trial Optional"

Mon, 12/18/2017 - 12:22
Notice NOT-AI-18-007 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R01 Clinical Trial Optional)

Mon, 12/18/2017 - 11:35
Funding Opportunity PA-18-348 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimers disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers.
Categories: NIH-Funding

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21 Clinical Trial Optional)

Mon, 12/18/2017 - 11:35
Funding Opportunity PA-18-347 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimers disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers.
Categories: NIH-Funding

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R15 Clinical Trial Not Allowed)

Mon, 12/18/2017 - 11:35
Funding Opportunity PA-18-473 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimers disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers.
Categories: NIH-Funding

Health-professional Education Partnership Initiative (HEPI) (R25 Clinical Trial Not Allowed)

Mon, 12/18/2017 - 11:07
Funding Opportunity RFA-TW-17-001 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this Fogarty International Center R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs by enhancing health workforce capacity in high HIV-burden, low-income countriesin sub-Saharan Africa; enhance the diversity of the biomedical, behavioral and clinical research workforce by encouraging interprofessional education initiatives to enhance team health care delivery; help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences in low-income countries to enhance capacity of US research projects; foster a better understanding of biomedical, behavioral and clinical research and its implications to improve capacity to develop, implement and evaluate evidence-based health services. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on courses for Skills Development;Research training; Mentoring Activities; Curriculum or Methods Development to increase Outreach to broad communities to enhance participation in skills development courses, curricula, and mentoring activities.
Categories: NIH-Funding

Tissue Mapping Centers for the Human BioMolecular Atlas Program (U54 Clinical Trials Not Allowed)

Mon, 12/18/2017 - 04:50
Funding Opportunity RFA-RM-17-027 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to establish state-of-the-art Tissue Mapping Centers (TMCs) that will generate high-resolution, multi-parameter maps of non-diseased human organs and systems. Centers will be expected to integrate and optimize all parts of the data generation pipeline, from tissue collection and preservation through to data integration, analysis and interpretation. Centers will also be expected to work closely with the other funded projects as part of the Human BioMolecular Atlas Program to catalyze development of a framework for mapping the human body with micron resolution.
Categories: NIH-Funding

Transformative Technology Development for the Human BioMolecular Atlas Program (UG3/UH3 Clinical Trials Not Allowed)

Mon, 12/18/2017 - 04:50
Funding Opportunity RFA-RM-17-025 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit transformative technologies that will significantly expand throughput, multiplexing and discrimination of biomolecules in human tissues for comprehensive mapping of individual cells and their context in human tissues. This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and systems that can be integrated, scaled and applied to multiple human tissues. The initial two-year UH2 phase will support accelerated development and demonstration of feasibility of these emerging, high impact technologies. The subsequent two-year UH3 phase will support validation in human tissues, optimization, scale-up, and generation of initial production level data. Funded projects will be expected to work closely as part of the Human BioMolecular Atlas Program to catalyze development of a framework for mapping the human body with high resolution.
Categories: NIH-Funding

Consequences of amyloid protein polymorphisms in Alzheimer's disease (R01 - Clinical Trial Not Allowed)

Mon, 12/18/2017 - 04:06
Funding Opportunity RFA-AG-18-025 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the consequences of amyloid protein polymorphism in regulation and initiation of early pathogenesis in Alzheimers disease (AD). Specifically, this FOA encourages collaborative approaches designed to identify and characterize the regulation of biochemical and cellular pathways that are responsible for the differential accumulation of various protein conformers in AD clinical subtypes.
Categories: NIH-Funding

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03 Clinical Trial Optional)

Mon, 12/18/2017 - 04:01
Funding Opportunity PAR-18-527 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research to deepen our knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies and strategies to treat patients in emergency departments and long range treatment.
Categories: NIH-Funding

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01 )

Mon, 12/18/2017 - 04:01
Funding Opportunity PAR-18-510 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support research to deepen our knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies and strategies to treat patients in emergency departments and long range treatment.
Categories: NIH-Funding

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21 Clinical Trial Optional )

Mon, 12/18/2017 - 04:01
Funding Opportunity PAR-18-509 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support research to deepen our knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies and strategies to treat patients in emergency departments and long range treatment.
Categories: NIH-Funding